Clinical Cancer Drugs - Volume 5, Issue 1, 2018

Background: Poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors have entered into the clinic rapidly and are becoming a powerful therapeutic tool, especially in the management of BRCA associated ovarian cancers. PARP inhibitors have exploited the homologous recombination deficiency, present in up to 50% of ovarian cancers, through synthetic lethality: A novel therapeutic approach to this disease. Objective: Read More

A tumour which can evolve within the colon and rectum is termed as colorectal cancer. These cancers are named as rectal or colon cancer based on their origin. The colorectal cancers evolve due to polyp formation either on the inner lining of the colon or rectum. Some of the polyps are leading to cancer over the series of several years, but all polyps do not develop cancer. The treatment of colorectal cancer is also possi Read More

Background: The migration of tumor cells is critical in spreading cancers through the lymphatic nodes and circulatory systems. Although arachidonic acid (AA) and its soluble metabolites have been shown to induce the migration of breast and colon cancer cells, the mechanism by which it induces such migration has not been fully understood. Objective: The effect of AA on migratory responses of the MDA-MB-231 c Read More

Background: Antibody-drug conjugates (ADCs) are an emerging technology consisting of an antibody, linker, and toxic agent, which have the potential to offer a targeted therapeutic approach. A novel target recently explored for the treatment of pancreatic cancer is guanylyl cyclase C (GCC). The objective of this study was to determine the anti-tumorigenic activity of TAK-264, an investigational ADC consisting of an anti Read More

Background: Acute promyelocytic leukemia (APL) is characterized by chromosomal translocations, which generate fusion oncogenic proteins. In 95% of cases, in frame fusion of the RARα gene to the PML gene, gives rise to the PML-RARα chimeric gene in patients with t(15;17)q22;q21. In addition, in 99% of cases, APL cells also express the germ cell-specific Cyclin A1 protein, which has been shown to contribute to APL-like Read More

Background: P-glycoprotein expression in tissues acts on pharmacokinetics and pharmacodynamics of drugs. In this context, the C1236T (rs1128503) variant in ATP binding cassette subfamily B member 1 (ABCB1) gene has been linked to inter-individual responses to many drugs. Objective: Our study evaluated the association between clinical and laboratory markers of breast cancer severity, including the recurren Read More